Exagen Inc. (XGN) Stock Overview
Explore Exagen Inc.’s financial performance, market position, analyst ratings, and future outlook.
Exagen Inc. (XGN)
Key Financials
Key Financials
Market Cap
191.3M
P/E Ratio
-9.25
EPS (TTM)
$-0.81
ROE
-1.22%
XGN Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Exagen Inc. (NASDAQ: XGN) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Exagen Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of XGN on the NASDAQ shows an RSI of 76.98, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $5.79 for the NASDAQ listing.
Key metrics behind Exagen Inc.'s NASDAQ-traded stock include a P/E ratio of -9.25 and a market capitalization of 191.3M. Combined with our AI analysis, these give both institutional and retail investors a clear view of XGN on the NASDAQ.